3rd SINDOFO Annual Consortium Meeting – Brief Overview

The 3rd SINDOFO Annual Consortium Meeting took place on November 13th, 2024, at The Hilton Riverside Hotel in New Orleans, at the margins of the Annual Meeting of the American Society of Tropical Medicine and Hygiene. The meeting was held as a hybrid meeting, to allow those consortium members not able to travel to New Orleans to also join the meeting virtually. Twenty-seven persons attended the 3rd Annual Consortium Meeting, from which 18 joined online. The objectives were to share actual status of the different Work Packages, with special interest on the timelines for completion of the project.
Jana Held, Project Coordinator, EKUT, began by acknowledging the significant achievements of the past year, highlighting the major steps forward in the project, and expressing gratitude to all consortium partners for their invaluable contributions in reaching these milestones. The remainder of the meeting was then also moderated by her.
Work Package 1: Project Coordination
Jana Held gave a broad summary and current state of the SINDOFO project, emphasizing on the approved amendment n°2, including a no-cost extension of the grant to December 31st, 2025, and the addition of Zydus Lifesciences Limited to the consortium as sponsor of the clinical trial. In preparation to the Oversight Committee of EDCTP´ Malaria Drugs Projects, she opened the discussions on the update of the project´s timelines for completion in December 2026.
Work Packages 2-5: Clinical Trial
Dearie Glory Okwu, Principal Investigator for ZYFER-1, CERMEL, shared an update on the ZYFER-1 study, which was initiated on August 30th, 2024 at CERMEL in Gabon. She also presented the challenges encountered by the site so far, as well as the mitigation measures put in place. Recruitment of cohort 1 was completed on October 26th, 2024 and shipment of PK samples for analysis in India is being planned.
Siddharth Brahmbhatt, Project Lead, Zydus Lifesciences Ltd., started with appreciating the efforts of the consortium for progression of the project, including initiation of the ZYFER-1 clinical trial. He then shared a short summary on the juvenile toxicity study on ZY19489, as well as on an ongoing ZY19489 proof of efficacy study in P. vivax.
Work Package 6: Training and Capacity Building
The WP6 part started with presentations from CNRST-IRSS and FM-CISM. Both sites are proposing to deliver trainings in 2025 for delegates of the SINDOFO consortium, as well as other EDCTP consortia.
Moussa Lingani, Study Coordinator, CNRST-IRSS, opened the floor, presenting a training on “Implementation of data management systems in clinical trials: requirements, procedures and tools”. The aim of this training would be to equip the participants with practical tools and knowledge for a proper implementation of clinical data management systems in accordance with required regulations. The training should be delivered in a hybrid format, including a 10 day in-person course in Burkina Faso.
Jessica Dalsuco, Principal Investigator, CISM-FM, proposed two trainings from her site. The first training on “Biosafety” should aim to ensure a safe and healthy working environment for all employees and partners, and that all clinical trial professionals follow the best biosafety practices to minimize health risks for both participants and professionals. The second training on “Research Methodology” will aim to ensure that all clinical trial professionals can conduct the research with the necessary quality, following ethical and regulatory standards, guaranteeing the safety of the participants and the validity of the results. Both training should be delivered as in-person trainings at CISM-FM, and total duration for both trainings is 5 working days.
Then, all PhD students recapitulated the progress of their individual projects.
Dearie Glory Okwu, PhD student at CERMEL, presented her topic entitled “Exploration of the Effectiveness of Antimalarial Drugs on Concomitant Schistosomiasis - Epidemiological, Clinical and Immunological Features”. Her PhD project aims i.) to evaluate the efficacy of Pyronaridine/artesunate on uncomplicated schistosomiasis, ii.) to evaluate the anti-schistosomal activity of the combination of ZY19489 and FQ in individuals co-infected with malaria and schistosomiasis, and iii.) to describe the distribution of malaria and schistosomiasis co-infection in Lambaréné and its surrounding areas. Completion of the PhD thesis is expected for December 2026.
Jessica Dalsuco, PhD student, CISM-FM, presented her topic titled “New Antimalarial Combinations for the Management of Uncomplicated and Severe Malaria in Mozambique, a High Malaria-Endemic Setting, with Focus in the Treatment of the Youngest and More Vulnerable Populations”. The objectives of her PhD thesis are i.) to evaluate the combination of a new antimalarial combination therapy, including 2 drugs (ZY19489 and Ferroquine) for the treatment of acute P. falciparum malaria in children and ii.) to characterize the paediatric population, specifically in infants < 6 months of age, suffering from malaria infection and/or disease”. PhD completion is expected by December 2026.
Tiampan Edwig Traore, PhD student, CNRST-IRSS, is working on a topic titled: “Evaluation of the Effect of Malaria Chemoprevention Strategies on P. falciparum Resistance Markers Dynamics and Host Immunity”. The PhD thesis aims i.) to assess the impact of IPTp-SP (Intermittent Preventive Treatment of malaria during pregnancy, using the antimalarial drug sulfadoxine-pyrimethamine [SP]) on the evolution of SP resistance markers 20 years after its implementation in pregnant women, ii.) to assess the impact of seasonal malaria chemoprevention (SMC) on the evolution of SP and amodiaquine resistance markers 8 years after its implementation in children under 5 years, iii.) to determine the level of P. falciparum resistance markers to ACTs over time in pregnant women and children under 5 years, and iv.) to assess the effect of IPTSc (Intermittent Preventive Treatment of malaria in school-aged children) on the seroprevalence of antibodies against a panel of P. falciparum antigens in school-aged children and their relationship with gametocytes carriage. Edwig is expected to completed her PhD by H1 2026.
Allan Otieno, PhD student, Strathmore University, is working on a topic titled: “Exploring the Disposition of Selected Artemisinin Combination Therapies in the Treatment of Malaria and Malaria Parasite Kinetics in Children with Sickle Cell Disease in Kisumu County”. The objective of the thesis is to investigate the drug disposition of selected artemisinin combination therapy and P falciparum kinetics in children with sickle cell disease and co-infected with malaria in Kisumu County, Kenya. Completion of the PhD thesis is expected by December 2026.
Ghyslain Mombo-Ngoma, Director Clinical Operations, CERMEL, closed the WP6 part by acknowledging the progress of the PhD students, as well as the initiative of the sites to deliver some additional trainings to the consortium. He then summarized the activities of WP6 during the year 2024, and presented the challenges of the sites with the purchase of equipment.
Following three hours of engaged discussion, Jana Held closed the meeting by acknowledging the partners for their valuable contributions to the project and the progress that had been made. The next consortium annual meeting will be held in Kigali, Rwanda, on the margins of the 12th EDCTP forum.

